NCT02040480View on ClinicalTrials.gov

Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 5, 2014

Primary Completion Date

April 4, 2014

Study Completion Date

April 4, 2014

Conditions
Cancer
Interventions
DRUG

GSK2110183 Gelatin Capsule

White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

DRUG

GSK2110183 IR Tablet

White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

Trial Locations (1)

2031

GSK Investigational Site, Randwick

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02040480 - Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib | Biotech Hunter | Biotech Hunter